Bronchodilator Agents
Mostrando 1-12 de 19 artigos, teses e dissertações.
-
1. Avaliação de hiperinsuflação dinâmica em pacientes com linfangioleiomiomatose através de teste de exercício cardiopulmonar e verificação da resposta à broncodilatação / Evaluation of dynamic hyperinflation in patients with lymphangioleiomyomatosis with cardiopulmonary exercise testing and verification of the response to bronchodilator
INTRODUÇÃO: Linfangioleiomiomatose (LAM) é uma doença rara, caracterizada pela proliferação de células musculares lisas atípicas ao redor de vias aéreas, vasos sanguíneos e linfáticos, com formação de cistos pulmonares difusos. Na prova de função pulmonar (PFP), a doença se caracteriza por padrão obstrutivo, aprisionamento aéreo e redução
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 23/10/2012
-
2. Resposta broncodilatadora imediata ao formoterol em doença pulmonar obstrutiva crônica com pouca reversibilidade = Immediate bronchodilator response to formoterol in poorly reversible chronic obstructive pulmonary disease
Objetivo: Avaliar, por meio de provas de função pulmonar, a eficácia broncodilatadora do formoterol após 30 min de sua administração em portadores de doença pulmonar obstrutiva crônica (DPOC) com pouca reversibilidade. Métodos: Estudo prospectivo incluindo 40 pacientes portadores de DPOC com resposta negativa ao broncodilatador de curta duração ut
Publicado em: 2010
-
3. Efeitos da nebulizaÃÃo com broncodilatadores carreados pelo heliox associada ao posicionamento corporal em pacientes com crise aguda de asma
Asthma is a respiratory pathology, the treatment of which is primarily pharmacological. Other therapeutic strategies may be used in clinical practice to aid in and/or optimize the treatment of this pathology. Heliox and physiotherapy have been studied with the aim of determining the effects of these resources on the treatment of individuals with asthma. Heli
Publicado em: 2009
-
4. The exercise of bronchodilatadors and oxygen alone and in combination on exercise performance in COPD / "Efeito da oxigenoterapia e dos broncodilatadores no desempenho físico de pacientes com DPOC"
Our objective was assess the effect of oxygen (O2) and bronchodilator (BD) on reduce exertional breathlessness and improve exercise tolerance in patients with COPD. Nebulization of 5 mg of salbutamol plus 500 ug ipratropium bromide followed by a six-minute walking test while breathing O2 were studient in 28 patients with severe COPD, breathless on exertion a
Publicado em: 2006
-
5. Agentes antiasmáticos modernos: antagonistas de receptores de leucotrienos cisteínicos
In the early 1990s numerous clinical trials with antileukotriene drugs confirmed the hypothesis that cysteinyl leukotrienes are important bronchoconstrictor agents in asthma. Newly released"antiasthmatic medications include antileukotriene agents which function either by blocking the interaction of leukotrienes with receptors or by inhibiting leukotriene syn
Química Nova. Publicado em: 2002-09
-
6. Time-dependent effect of prostaglandin E2 inhalation on airway responses to bronchoconstrictor agents in normal subjects.
Studies were performed to investigate whether hyperresponsiveness of the airways could be induced in normal subjects by inhalation of prostaglandin E2 (PGE2). During the initial bronchodilator phase of PGE2 action the bronchoconstrictor effect of inhaled histamine was significantly antagonised. When bronchoconstrictor challenges were started shortly after th
-
7. Response of blood gas tensions to aminophylline and isoprenaline in patients with asthma 1
Aminophylline and isoprenaline, two drugs widely used in the management of asthma, have a pulmonary vasodilator action as well as a bronchodilator action. If regional pulmonary vasoconstriction in poorly ventilated parts of the lungs is a significant compensatory phenomenon in asthma, the effects of administration of these agents on gas exchange would depend
-
8. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease.
BACKGROUND--Inhaled anticholinergics and beta agonists are widely used in the treatment of patients with chronic obstructive pulmonary disease (COPD). However, dosage requirements have not been thoroughly evaluated and comparative dose-response data for these agents are limited. METHODS--Twenty men with stable COPD of mean (SD) age 69.4 (5.8) years and FEV1
-
9. Alterations in Cyclic Adenosine Monophosphate Metabolism in Human Bronchial Asthma. I. LEUKOCYTE RESPONSIVENESS TO β-ADRENERGIC AGENTS
In an effort to better define the role of βadrenergic blockade in human bronchial asthma, peripheral blood leukocytes and lymphocytes from individuals with this condition were studied for possible alterations in cyclic AMP metabolism. Using a previously described radioimmunoassay to measure cyclic AMP, cells from asthmatic subjects were shown to have a high
-
10. Beta-blockers and asthma.
In a single-blind, randomised, crossover study in 10 asthmatic patients, the effects of approximately equipotent oral doses of 3 cardioselective beta-blockers-atenolol (100 mg), metoprolol (100 mg), and acebutolol (300 mg)-and 4 non-cardioselective beta-blockers-proranolol (100 mg), oxprenolol (100 mg), pindolol (5 mg), and timolol (10 mg) upon FEV1 were com
-
11. Bronchodilator aerosol administered by metered dose inhaler and spacer in subacute neonatal respiratory distress syndrome.
There is increasing evidence that bronchodilators are effective in ventilator dependent preterm infants. The effects of single doses of salbutamol (400 micrograms), ipratropium bromide (72 micrograms), and placebo (four puffs) given by metered dose inhaler and spacer (MDIS) were examined in 10 ventilated preterm infants, with a mean birth weight of 800 g at
-
12. Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma?
The second messenger cyclic nucleotides, cyclic AMP and cyclic GMP, mediate relaxation of airways smooth muscle and suppression of multiple inflammatory cell functions. The intracellular concentrations of these cyclic nucleotides are regulated by a superfamily of phosphodiesterase (PDE) enzymes which break down cAMP and cGMP and, thereby, affect airway tone